Standard Repeat Biopsies During Active Surveillance for Prostate Cancer: Are They Necessary in the Magnetic Resonance Imaging Era?

Roderick C N van den Bergh; Ivo G Schoots; Philip A Cornford; European Association of Urology Prostate Cancer Guidelines Panel

doi:10.1016/j.eururo.2024.09.014

Standard Repeat Biopsies During Active Surveillance for Prostate Cancer: Are They Necessary in the Magnetic Resonance Imaging Era?

Eur Urol. 2025 Jan;87(1):5-7. doi: 10.1016/j.eururo.2024.09.014. Epub 2024 Sep 25.

Authors

Roderick C N van den Bergh¹, Ivo G Schoots², Philip A Cornford³; European Association of Urology Prostate Cancer Guidelines Panel

Affiliations

¹ Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address: [email protected].
² Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
³ Department of Urology, Liverpool University Hospitals NHS Trust, Liverpool, UK.

PMID: 39327115
DOI: 10.1016/j.eururo.2024.09.014

Abstract

Active surveillance (AS) remains an important part of the efforts to decrease overtreatment of prostate cancer. The increasing use of magnetic resonance imaging (MRI) can reduce the need for repeat biopsy during AS. If MRI findings remain unchanged and clinical characteristics such as prostate-specific antigen density are favourable, the relative risks and benefits of repeat biopsy should be discussed with individual patients.

Publication types

Editorial

MeSH terms

Biopsy
Humans
Magnetic Resonance Imaging*
Male
Prostate / diagnostic imaging
Prostate / pathology
Prostate-Specific Antigen / blood
Prostatic Neoplasms* / diagnostic imaging
Prostatic Neoplasms* / pathology
Watchful Waiting*

Substances

Prostate-Specific Antigen